What is Axogen?
Axogen operates at the intersection of biotechnology and medical technology, focusing on the complex challenges of peripheral nerve injury. The company develops and commercializes a comprehensive suite of products designed to facilitate nerve regeneration and restore patient function. By addressing critical gaps in surgical outcomes, Axogen has established a robust market presence, leveraging proprietary technologies that provide surgeons with reliable, effective tools for nerve repair. Its commitment to clinical excellence and patient-centric innovation has made it a cornerstone of modern neuro-regenerative therapy.
How much funding has Axogen raised?
Axogen has raised a total of $99.3M across 8 funding rounds:
Series B
$7.8M
Series C
$12.1M
Debt
$2.6M
Debt
$3.7M
Debt
$3M
Stock Offering
$18M
Share Placement
$17.1M
Debt
$35M
Series B (2006): $7.8M with participation from Springboard Capital
Series C (2007): $12.1M led by Cardinal Partners, Springboard Capital II, DeNovo Ventures, and Accuitive Medical Ventures
Debt (2009): $2.6M, investors not publicly disclosed
Debt (2011): $3.7M, investors not publicly disclosed
Debt (2011): $3M, investors not publicly disclosed
Stock Issuance/Offering (2013): $18M, investors not publicly disclosed
Share Placement (2015): $17.1M led by Essex Woodlands
Debt (2020): $35M supported by Oberland Capital Management LLC
Key Investors in Axogen
Cardinal Partners
A premier venture capital partnership focused exclusively on healthcare, specializing in early-stage financing to drive innovation and extraordinary returns.
Essex Woodlands
A healthcare growth equity firm that partners with management teams in pharmaceuticals and MedTech to provide capital and strategic guidance for business acceleration.
Accuitive Medical Ventures
A market-driven venture capital firm dedicated to revolutionary medical device technology, leveraging deep industry relationships to build long-term shareholder value.
What's next for Axogen?
With the infusion of recent capital, Axogen is well-positioned to accelerate its commercial expansion and deepen its research and development pipeline. The company's strategic roadmap likely involves scaling its manufacturing capabilities to meet growing global demand while simultaneously pursuing clinical trials to expand the indications for its nerve repair portfolio. As the firm transitions into its next phase of growth, the focus will remain on maintaining its competitive advantage through technological differentiation and strategic partnerships, ultimately aiming to set new standards in the treatment of nerve-related trauma and disease.
See full Axogen company page
